Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Secukinumab in Behçet's Uveitis
NCT00995709Phase 3Completed
- Sponsor
- Novartis
- Start
- Oct 2009
- Primary completion
- Jul 2010
- Modality
- Monoclonal Antibodies
- Countries
- 17
01
Overview
A Phase 3 trial of secukinumab in Behçet's disease (BD), sponsored by Novartis. Started Oct 2009; status: completed.
02
Drugs
secukinumab
03
Conditions
Behçet's disease (BD)
Beyond the preview
Go deeper on NCT00995709.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00995709.